Bromazepam Hemofarm

Quick links

Choose a section

Quick links to important sections

Advertisements

Bromazepam Hemofarm

Advertisements
Advertisements

Overview of Bromazepam Hemofarm

Property Description
Active ingredient Bromazepam (INN)
Form Tablet (Oral)
Pharmacological class Anxiolytic Benzodiazepine
Common use Relief of severe anxiety and tension
Origin Synthetic compound

Bromazepam Hemofarm is a specific pharmaceutical preparation supplied as a tablet, containing the active substance Bromazepam. As a product formulated by Hemofarm, it is part of their established line of medications. Bromazepam is classified as an anxiolytic and a psycholeptic agent, belonging to the high-level group of Central Nervous System (CNS) depressants, primarily intended to manage conditions associated with severe anxiety and emotional tension. The active substance is a widely recognized synthetic compound derived from the benzodiazepine chemical structure.


What Type of Medicine is Bromazepam Hemofarm?

Bromazepam Hemofarm is categorized pharmacologically as an anxiolytic benzodiazepine, a class clinically recognized for its reliable calming effects. This classification means its primary function is to relieve severe anxiety, distinguishing it from other psycholeptic agents like mood stabilizers or antipsychotics. The action of the drug fundamentally involves enhancing the effectiveness of the brain’s primary inhibitory signals, which helps to slow down the rate of overactive nerve signaling. This core effect is supported by extensive pharmacological studies and is the basis for its generalized calming effect, promoting both mental and physical relaxation.

Composition and Physical Form

In terms of composition, the medicine is manufactured as a single-ingredient product presented in an oral dosage form, specifically as a tablet. Each tablet contains a precise amount of the active ingredient, Bromazepam, blended with standard solid pharmaceutical excipients that form the inert base or vehicle of the preparation. This established and stable oral route of administration differentiates it from specialized liquid or injectable forms.

General Purpose as an Anxiolytic

The general purpose of Bromazepam is to address the intense symptoms associated with emotional tension and acute agitation. Its classification as a potent anxiolytic is universally detailed in authoritative reviews, confirming its utility when a powerful calming action is required. The general consensus is that this medicine helps to alleviate the physical and psychological distress caused by excessive CNS activity, making it appropriate for scenarios requiring rapid, effective stabilization and relaxation.

Advertisements

What side effects are possible with Bromazepam Hemofarm?

Possible Side Effects and Safety Information

This section describes the officially documented adverse reactions and safety characteristics of Bromazepam Hemofarm, based on regulatory labeling from government health authorities.

Adverse Reaction Classification

Adverse effects are documented across various System-Organ Classes (SOCs), with primary effects observed in the Nervous System and Psychiatric Disorders categories. Adverse reactions classified as Common in regulatory documents include drowsiness, sedation, ataxia (loss of coordination), dizziness, fatigue, and muscle weakness. Other reported effects may affect the eyes, gastrointestinal system, or skin, with some occurrences classified as Not Known (frequency cannot be estimated from available data).

Time- and Dose-Related Safety Patterns

Regulatory information specifies that the risk of developing physical and psychological dependence is directly correlated with the dose and duration of treatment. Tolerance to the sedative effect may develop over the course of therapy. Anterograde amnesia is noted as a possible effect, with the risk increasing at higher dosages. Upon cessation, the possibility of withdrawal syndrome and rebound phenomena (recurrence of symptoms in an enhanced form) is officially documented.

Serious Adverse Reactions and Safety Constraints

The label lists serious potential adverse reactions, including severe respiratory and/or cardiovascular depression, particularly when used concurrently with other CNS depressants or alcohol. Individuals with severe hepatic impairment are constrained from use due to the risk of precipitating hepatic encephalopathy. Furthermore, the safety profile highlights that older adults are at an increased risk of dose-related adverse events, including falls and fractures, due to the drug’s effects on coordination and sedation.

These safety classifications structure the formal understanding of Bromazepam's risk profile, focusing on officially recognized adverse outcomes and safety limitations tied to patient populations and exposure duration.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented signs of Bromazepam overdose and the specific actions required for seeking urgent medical assistance, as established in government regulatory documents.

Overdose of Bromazepam alone generally leads to a mild-to-moderate intensification of its CNS depressant effects. However, the most severe and life-threatening outcomes are explicitly associated with co-ingestion with other Central Nervous System (CNS) depressants.

Documented Manifestations and Severe Outcomes

Classification Signs and Outcomes (Regulatory Basis)
Mild-to-Moderate Drowsiness, lethargy, ataxia (incoordination), and a confusional state.
Severe Outcomes Profound sedation, respiratory depression, coma, and death are documented risks, primarily when Bromazepam is combined with substances like alcohol or opioid medicines.

Required Emergency Actions

Immediate medical attention is mandatory for any suspected overdose. Patients or caregivers must contact a healthcare practitioner, hospital emergency department, or regional Poison Control Centre immediately, regardless of whether symptoms are present.

Urgent care is specifically required if the patient exhibits severe signs, including passing out (unresponsiveness), being very dizzy or sleepy, or experiencing slow or troubled breathing. Management is primarily symptomatic and supportive, with close patient monitoring. The antidote flumazenil is noted as available for consideration in some official documents.

Advertisements

Therapeutic Uses of Bromazepam Hemofarm

What Bromazepam Hemofarm Treats: Main Uses and Benefits

Bromazepam is commonly used to help manage various symptoms and conditions marked by heightened patient distress, primarily used in areas where short-term symptom management is appropriate for certain distressing symptoms. It is relevant for easing symptom clusters that may become intense or disruptive. The medication is commonly used to help manage symptoms associated with periods of heightened symptoms, such as anxiety.

The medication is applied across domains where additional symptomatic support is needed, including pronounced psychological distress, physical symptoms of tension, and temporary sleep disturbances caused by anxiety. It helps address symptoms that interfere with daily comfort.

Quick Fact: Symptomatic Relief

It is commonly used when short-term symptomatic assistance is needed during phases of increased distress, such as those presenting with acute or episodic manifestations of anxiety. This supportive relief assists with maintaining functional stability when symptoms are more noticeable and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

  1. Health Canada Product Monograph
Advertisements

Eligibility and Restrictions for Use

Bromazepam Hemofarm is a benzodiazepine indicated for short-term use in adults for conditions such as severe anxiety that is disabling or causing extreme distress. However, it is strictly contraindicated for several populations due to safety risks.

Contraindications

This medicine must not be used by patients with:

  • Known hypersensitivity to benzodiazepines or any component of the formulation.
  • Severe respiratory insufficiency (including chronic obstructive pulmonary disease with incipient respiratory failure).
  • Severe hepatic impairment (severe liver failure) due to the risk of hepatic encephalopathy.
  • Myasthenia gravis (a muscle-weakening condition).
  • Sleep apnoea syndrome.
  • Narrow-angle glaucoma.
  • Rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption (due to lactose content).

Restrictions and Special Considerations

  • Pediatric Patients: Use is not recommended for children or adolescents under 18 years of age (or less than 12 years in some official documents) as safety and efficacy have not been established.
  • Elderly Patients: Should receive a reduced dose and be monitored closely due to increased sensitivity to adverse effects like sedation and the risk of falls.
  • Hepatic or Renal Impairment: Patients with mild to moderate liver or kidney dysfunction should use the lowest possible dose with caution.
  • Substance Abuse: Use requires extreme caution in patients with a history of alcohol or drug abuse due to the increased risk of dependence.
  • Psychiatric Conditions: It is not recommended as a sole therapy for depression or psychosis.
Advertisements

What should I know about interactions with other medicines?

The interaction profile for Bromazepam is officially categorized by two principal domains: agents that enhance its central nervous system (CNS) effects and medicines that inhibit its metabolic breakdown.

Interaction Type Interacting Medicines and Substances Regulatory Statement
Pharmacodynamic Enhancement Opioids, Alcohol, CNS depressants (e.g., Antipsychotics, Sedatives) Co-administration with Opioids and Alcohol is restricted due to the significant risk of profound sedation, coma, and respiratory depression. Use with other CNS depressants causes an officially documented enhancement of the central depressive effect.
Pharmacokinetic Inhibition Fluvoxamine, Cimetidine, Strong CYP3A4 Inhibitors These agents impede metabolism, thereby altering systemic exposure. Fluvoxamine significantly increases Bromazepam exposure, officially quantified as a 2.4-fold increase in AUC. Cimetidine reduces clearance by approximately 50%.

Population-specific cautions are noted in regulatory documents regarding interaction risk. Elderly and Debilitated Patients have an increased susceptibility to outcomes such as over-sedation resulting from co-administration. Caution is also advised for patients with Mild to Moderate Hepatic Impairment, as benzodiazepines may contribute to the precipitation of hepatic encephalopathy. The official labeling states that the effect of food on Bromazepam absorption is currently unknown.

Advertisements

Mechanism of Action

Molecular Interaction: Enhancing Inhibitory Signals

Bromazepam functions as a positive allosteric modulator that binds specifically to the benzodiazepine site on the GABA-A receptor complex, the brain's primary inhibitory target. This precise interaction increases the receptor's sensitivity to the natural neurotransmitter GABA, leading to a higher frequency of chloride ion channel openings. This initiates the core molecular cascade and leads to postsynaptic membrane hyperpolarization.

Systemic Consequence: Dampening Neural Excitability

The resulting influx of chloride ( Cl^-) ions causes widespread hyperpolarization of nerve cells across key areas, including the Limbic System and cortical pathways. This dampening of neural excitability limits excessive and rapid signaling, which is associated with a reduction in central arousal and modified physiological dynamics. This mechanism is also centrally involved in the inhibition of polysynaptic reflexes, resulting in reduced skeletal muscle tone.

Mechanism Constraints: Dependency and Adaptation

The mechanism is entirely reliant on the presence of endogenous GABA for its action, defining it as a modulator with an inherent ceiling effect on the magnitude of the response. Furthermore, continuous engagement of the receptor can lead to molecular adaptations, such as tolerance development, where the receptor complex becomes less responsive over time, constraining the long-term extent of the allosteric modulation.

Advertisements

Dosage and Administration Information

Bromazepam is administered via the oral route as tablets, which may be scored for dose division, or as an oral solution. Dosing is determined individually, beginning at a low initial dose and gradually increasing. The typical daily dosage for outpatients ranges from 6 mg to 18 mg, administered in divided doses. In cases of greater severity or for hospitalized patients, higher doses may be used, up to a maximum of 60 mg in divided doses, reserved for exceptional scenarios.

The medicine is prescribed for short-term use only. The total duration of therapy, including the necessary period of gradual withdrawal, should not exceed 8 to 12 weeks. The administration schedule requires the total dose to be divided and taken throughout the day, often with the largest portion or the entire low dose taken in the evening. It is advised to take the medicine on an empty stomach.

Administration rules are explicitly adjusted for specific populations:

Population Group Labeled Administration Principle
Older Adults Require a lower initial dose, generally not exceeding 3 mg daily in divided doses.
Hepatic Impairment The lowest possible dose must be used due to altered elimination.
Pediatric Patients Not recommended due to insufficient evidence regarding safety and efficacy.

Discontinuation of the medicine must always involve a gradual tapering of the dose. Abrupt cessation is a key procedural constraint that must be avoided to adhere to the official use protocol.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bromazepam Hemofarm

Evidence for use in Pathological Anxiety and Tension States

Research examined the use of Bromazepam in adults experiencing pathological anxiety and emotional tension. Researchers primarily used short-term Randomized Controlled Trials (RCTs) and systematic reviews to explore how symptoms change over time in these populations. These studies monitored outcomes related to symptom intensity or variability, typically using standardized anxiety rating scales. Findings describe patterns observed in the studies related to symptom evolution during the short follow-up durations. Studies monitored patient-reported outcomes describing perceived discomfort related to anxiety and tension.

Evidence for Anxiety with Associated Somatic Symptoms

Studies explored the use of Bromazepam in patients whose anxiety was accompanied by significant physical complaints, such as muscular tension or stomach upset. These research efforts monitored outcomes related to physical discomfort alongside anxiety scale changes. Research describes patterns where outcomes related to systemic imbalance were monitored alongside changes in anxiety measures during the short study period. Evidence contributes to understanding symptom patterns, but findings were mixed when changes in purely physical complaints were monitored, as these are often treated as secondary outcomes in the research.

Long-Term Outcomes and Research Gaps

The research examined the length of time that symptom patterns were monitored following treatment. The majority of initial evidence is relevant in trials assessing short-term or episodic symptom patterns. Consequently, long-term outcomes are not fully established for the use of Bromazepam beyond the short intervals examined in the primary efficacy trials. There is limited information for long-term outcomes, particularly concerning functional measures. Research describes patterns related to changes in tolerance status observed in some studies, but their evolution over long periods is not well characterized by controlled research. Furthermore, limited data are available for children, adolescents, and pregnant populations.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Bromazepam Hemofarm (FAQ)

Q: How quickly does Bromazepam Hemofarm start working after taking it?

A: Official regulatory data suggests that the concentration of Bromazepam in the blood, which is generally associated with maximum clinical effect, is reached approximately one to four hours after a tablet is taken by mouth. The time it takes for effects to become noticeable can vary between individuals.

Q: Can Bromazepam Hemofarm help with trouble sleeping or insomnia?

A: Bromazepam is primarily an anti-anxiety medicine indicated for emotional disorders that include symptoms such as tension. As an anxiolytic, its effects on anxiety and tension may secondarily help with related sleep difficulties, but it is not typically labeled as a standalone primary sleep disorder treatment.

Q: How long does the effect of one dose of Bromazepam Hemofarm usually last?

A: The length of time the substance remains in the body can be estimated using its elimination half-life, which is approximately 20 hours in healthy adults. The half-life refers to the time needed for the amount of drug in the body to be reduced by half.

Q: Are there any known issues with taking Bromazepam Hemofarm while breastfeeding (informational)?

A: Information from regulatory sources indicates that Bromazepam can pass into breast milk. Although adverse effects on a breastfed infant are rare, regulatory guidance highlights the need for caution in this area.

Q: Can Bromazepam Hemofarm make anxiety worse initially before it gets better?

A: Paradoxical reactions such as increased anxiety, agitation, restlessness, and irritability are known to occur with benzodiazepine medicines, particularly in sensitive groups. If such effects occur, a healthcare professional typically re-evaluates the treatment plan.

Q: What is the typical starting time for doctors to reassess treatment with Bromazepam Hemofarm?

A: Official guidance emphasizes that the medicine is for short-term use and that the need for continued treatment should be regularly reassessed by a healthcare professional. Reassessment is crucial if symptoms improve.

Q: Does Bromazepam Hemofarm show up on standard drug tests?

A: Bromazepam is metabolized in the liver and its breakdown products are excreted primarily through the urine. Specialized tests are capable of detecting Bromazepam or its metabolites in biological fluids like urine.

Q: Is it possible for Bromazepam Hemofarm to cause mood swings or irritability?

A: Yes, official product information includes paradoxical reactions under adverse effects. These reactions, which can occur with benzodiazepines, include the potential for irritability, aggressiveness, and mood swings.

Q: How important is it to take Bromazepam Hemofarm at the exact same time every day?

A: The total daily dose is often split and administered in divided doses throughout the day. Taking the medicine consistently helps maintain steady drug levels in the body, which can be helpful for symptom management.

Q: Why do doctors often try non-benzodiazepine options before prescribing Bromazepam Hemofarm?

A: The use of Bromazepam is generally limited to short courses of treatment. This is due to the risk of developing dependence and tolerance, which suggests that long-term, non-dependency-forming agents are preferred as initial or maintenance treatment.

Q: How does Bromazepam Hemofarm fit into a broader anxiety treatment plan (e.g., therapy)?

A: Regulatory consensus suggests short-term use of Bromazepam as an adjunct (additional) treatment. It is intended to help stabilize severe symptoms, often alongside primary treatments such as psychological or behavioral therapy.

Q: Does Bromazepam Hemofarm interact with birth control pills?

A: Clinical studies reviewed by regulatory bodies have shown that the process of how the body handles Bromazepam is not significantly affected by the co-administration of oral contraceptive steroids (birth control pills).

Q: Does Bromazepam Hemofarm cause long-term effects on memory or cognitive function?

A: Official safety data indicates that long-term use of benzodiazepines, as a drug class, has been associated with some cognitive impairment, including effects on memory. Due to limited long-term data, health authorities recommend monitoring during prolonged use.

Q: What research studies support the use of Bromazepam Hemofarm for panic disorders?

A: The drug is officially indicated for severe anxiety and tension. Consensus clinical guidelines suggest that Bromazepam is an option for the short-term management of Panic Disorder symptoms, although it may not be the initial treatment of choice.

Q: Why do some people feel 'zombie-like' or emotionally numb on Bromazepam Hemofarm?

A: Official adverse effect listings include common reactions like drowsiness, sedation, and fatigue. These effects stem from the drug's action as a central depressant and may be subjectively perceived as feeling emotionally distant or physically slow.

Q: Is Bromazepam Hemofarm used for conditions other than anxiety?

A: Official product information indicates its use for emotional disorders and anxiety, including associated physical complaints and tension. It is not recommended as a sole treatment for depression or psychosis.

Q: Are there any long-term health risks associated with taking Bromazepam Hemofarm as prescribed?

A: Regulatory documents explicitly state that the long-term efficacy and safety of benzodiazepines are not fully established. Regulatory guidance recommends regular monitoring of the blood count and liver function during prolonged use.

Q: Why is the use of Bromazepam Hemofarm generally limited to short-term treatment?

A: The treatment duration is officially limited because the risks of developing both physical and psychological dependence, as well as tolerance to the drug's effects, increase significantly the longer the medicine is taken.

Q: Does Bromazepam Hemofarm interact with common heartburn medications or antacids?

A: Yes, a medicine used for heartburn, Cimetidine, is listed in interactions. Cimetidine is known to significantly reduce Bromazepam's clearance from the body, which can lead to increased drug exposure and stronger effects.

Q: How is Bromazepam Hemofarm metabolized and cleared out of the body?

A: Bromazepam is primarily processed (metabolized) in the liver via an enzyme system known as hepatic microsomal oxidation. The resulting inactive substances are then mostly excreted from the body via the urine.

Q: Are there any known withdrawal symptoms besides increased anxiety after stopping Bromazepam Hemofarm?

A: Yes, official safety data lists numerous potential symptoms of withdrawal syndrome. These may include headaches, muscle pain, insomnia, restlessness, confusion, irritability, palpitations, panic attacks, vertigo, and abnormal body sensations.

Q: Does Bromazepam Hemofarm affect blood pressure or heart rate?

A: A drop in blood pressure (hypotension) has been reported, although this is rare. Caution is advised, particularly for older adults. Severe cardiovascular depression is listed as a serious, but infrequent, potential adverse effect.

Q: What is the risk of overdose associated with Bromazepam Hemofarm alone?

A: When taken in isolation, an overdose typically results in central nervous system depression, such as slurred speech and severe drowsiness. The risk of severe, life-threatening respiratory depression is greatly increased when combined with other CNS depressants, such as alcohol.

Q: Why is a slow reduction (tapering) necessary when stopping Bromazepam Hemofarm?

A: A gradual reduction in dose (tapering) is officially mandated to minimize the potential for developing withdrawal symptoms. Tapering also helps mitigate the risk of rebound phenomena, which is when the original symptoms return in a more intense form.

Advertisements

How should Bromazepam Hemofarm be stored and disposed of?

Storage and Disposal Requirements

The official regulatory information for Bromazepam outlines specific requirements to maintain product stability and ensure proper disposal.

Storage Conditions

Requirement Official Statement
Temperature Store under normal conditions (typically controlled room temperature).
Protection Keep in the original container, tightly closed, to protect from moisture and light. Avoid excessive heat.
Child Safety Store locked up and out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired Bromazepam Hemofarm must follow local and national regulations. The official labeling mandates that the medicine and its container must not be disposed of in household trash or wastewater systems to prevent environmental contamination. Patients should utilize designated drug take-back programs or authorized collection points for disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bromazepam Hemofarm found in:

A-Z Index: